Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A trial of a new inhaled antiviral drug for COVID-19 has shown positive results and the drug is now moving into a larger international phase 3 trial of hospitalised patients.

Digital illustration of a human with a transparent body and model of coloured lungs inside with coronavirus particle models.

A new treatment, a protein called interferon beta or SNG001, has been developed with results from the phase 2 trial published in the Lancet Respiratory Medicine journal. The study showed that hospitalised COVID-19 patients on nebulised interferon bets recovered quicker and that the drug was safe.

Interferon beta, produced naturally by the body when it gets a viral infection, is inhaled directly into the lungs of patients with coronavirus using a nebuliser, with the aim of reducing viral load and stimulating an immune response. Oxford University Hospitals contributed 10% of the patients in the phase 2 trial.

The large phase 3 trial, which is expected to involve 900 participants and take place in up to 20 NHS sites, has been deemed an urgent public health research study by the Department of Health and Social Care, and will be prioritised for set-up and delivery across the NHS by the NIHR Clinical Research Network over the coming months.

The full story is available on the NIHR Oxford Biomedical Research Centre website

The story is also featured on the MRC Weatherall Institute of Molecular Medicine website

Similar stories

Language learning difficulties in children linked to brain differences

A new study using MRI has revealed structural brain changes in children with developmental language disorder (DLD), a common but under-recognised difficulty in language learning. Children with DLD aged 10-15 showed reduced levels of myelin in areas of the brain associated with speaking and listening to others, and areas involved in learning new skills. This finding is a significant advance in our understanding of DLD and these brain differences may explain the poorer language outcomes in this group.

The Gene Therapists Headline at Glastonbury 2022

Rosie Munday writes about her experience taking science to the masses at the Glastonbury Festival.

New research reveals relationship between particular brain circuits and different aspects of mental wellbeing

Researchers at the University of Oxford have uncovered previously unknown details about how changes in the brain contribute to changes in wellbeing.

Night-time blood pressure assessment is found to be important in diagnosing hypertension

Around 15% of people aged 40-75 may have a form of undiagnosed high blood pressure (hypertension) that occurs only at night-time. Because they do not know about this, and therefore are not being treated for it, they are at a higher risk of cardiovascular disease such as stroke, heart failure, and even death, suggests new research from the University of Oxford published in the British Journal of General Practice.

Major new NIHR Global Health Research Unit to focus on data science and genomic surveillance of antimicrobial resistance

The Centre for Genomic Pathogen Surveillance, part of the Big Data Institute at the University of Oxford, has been awarded funding worth £7m for their work as an NIHR Global Health Research Unit (GHRU) for the next five years. The Centre’s research and capacity building work focuses on delivering genomics and enabling data for the surveillance of antimicrobial resistance (AMR).